Clinical Trials · NCT05093634
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 296
- Start date
- Dec 2021
- Locations
- 56 sites, 10 countries
- Primary endpoint
- Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI